Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 9Plasma cell 2Gastrointestinal 2Genitourinary 1Breast 1

Conditions

Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
L-BLP25 × Plasma cell × Clear all
NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT01094548 2016-02-22

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
34 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡